A multicentre, randomised, double-blind, tacrolimus dual therapy-controlled, parallel group, multiple oral dose study to evaluate the safety, tolerability, efficacy and pharmacokinetics of FK778 in liver transplant patients receiving standard tacrolimus (FK506) and steroids therapy

Trial Profile

A multicentre, randomised, double-blind, tacrolimus dual therapy-controlled, parallel group, multiple oral dose study to evaluate the safety, tolerability, efficacy and pharmacokinetics of FK778 in liver transplant patients receiving standard tacrolimus (FK506) and steroids therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2007

At a glance

  • Drugs FK 778 (Primary)
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 24 Jun 2007 Results dat presented at ATC 2007 (1027726).
    • 02 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top